Photo of Joe Lennerz from pathologyoutlines.com
Apr 12, 2024, 05:34
Joe Lennerz: Quickly sharing a fantastic paper on tumour infiltrating lymphocytes in triple-negative breast cancer
Joe Lennerz, Chief Scientific Officer at BostonGene, shared on LinkedIn:
“Quickly sharing a fantastic paper on tumour infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC). Bottom line: In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival.
These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC. Link to publication.”
Source: Joe Lennerz/LinkedIn